{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
etoposide phosphate
to a specific field?
Status:
Investigational
Source:
NCT02073838: Phase 2 Human clinical trial Completed Leukemia, Myeloid, Acute/genetics/metabolism
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Status:
Investigational
Source:
NCT01014208: Phase 3 Interventional Completed Lymphoma, Large-Cell, Diffuse
(2010)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
NCT04150042: Phase 1 Interventional Recruiting Pancreatic Adenocarcinoma Metastatic
(2021)
Source URL:
Class (Stereo):
CHEMICAL (EPIMERIC)
Status:
Investigational
Source:
NCT03515538: Phase 2 Interventional Completed Oral Mucositis
(2018)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
RRX-001, also known as ABDNAZ, is a dinitroazetidine derivative with potential radiosensitizing activity. Upon administration, RRx-001 is able to dilate blood vessels, thereby increasing tumor blood flow and thus improving oxygenation to the tumor site. By increasing oxygen levels, these tumor cells may be more susceptible to radiation therapy. Tumor hypoxia is correlated with tumor aggressiveness, metastasis and resistance to radiotherapy. In mouse models, RRx-001 administered intravenously as a single agent was equipotent to cisplatin while better tolerated. RRx-001 also showed activity as a radiosensitizer in both in vitro and in vivo models. The activity of RRx-001 is thought to be associated with a nucleophilic substitution by circulating thiol compounds and covalent binding of RRx-001 to cysteinyl residues in Hb, followed by the generation of nitrogen oxides. During 2014-2015 EpicentRx has launched Phase 2 trials in brain, colorectal, non-small cell lung, small cell lung and cholangiocarcinoma both alone and in combination. The anti-proliferative effects of RRx-001 are not explainable via a single mechanism. RRx-001 exerts its anti-proliferative effect, at least partially, through interference with glucose 6 phosphate dehydrogenase (G6PD), a key enzyme in the pentose phosphate pathway, responsible for maintaining adequate levels of the major cellular reductant, NADPH.
Status:
Investigational
Source:
NCT01081782: Phase 2 Interventional Completed Multiple Sclerosis
(2010)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Ceralifimod (ONO-4641) is an oral, selective Sphingosine 1-phosphate receptor 1 and 5 agonist. It was studied in the phase 2 trials for the treatment of multiple sclerosis, however, further, development was discontinued.
Status:
Investigational
Source:
NCT02723292: Not Applicable Interventional Completed Adolescent Problems
(2011)
Source URL:
Class (Stereo):
CHEMICAL (MIXED)
Status:
Investigational
Source:
INN:fosalvudine tidoxil [INN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Heidelberg Pharma Research developed fosalvudine tidoxil, a prodrug derived from the nucleoside reverse transcriptase inhibitor alovudine, for the treatment of HIV infections. This drug had reached phase II clinical trials before its development was discontinued.
Status:
Investigational
Source:
USAN:POTASSIUM CHLORIDE K 42 [USAN]
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Potassium cation K-42 is a radioactive tracer. It was used to study K exchanges across the myocardial cell wall and measuring uptake of isotope by the myocardium, to measure of potassium ion influx in Chinese hamster ovary (CHO) cells and other researches related to K-transport in vivo and in vitro.
Status:
Investigational
Source:
Circ Heart Fail. Jul 2022;15(7):e009120.: Not Applicable Human clinical trial Completed Heart Failure/diagnosis
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Class (Stereo):
CHEMICAL (ABSOLUTE)
